Skip Navigation


NDT Advance Access originally published online on February 13, 2007
Nephrology Dialysis Transplantation 2007 22(5):1301-1304; doi:10.1093/ndt/gfl847
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow An erratum has been published
Right arrow All Versions of this Article:
22/5/1301    most recent
gfl847v2
gfl847v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Dimitrov, J. D.
Right arrow Articles by Kaveri, S. V.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dimitrov, J. D.
Right arrow Articles by Kaveri, S. V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Sialylated therapeutic IgG: a sweet remedy for inflammatory diseases?*

Jordan D. Dimitrov{dagger}, Jagadeesh Bayry{dagger}, Sophie Sibéril and Srini V. Kaveri

INSERM UMRS 872 Equipe 16- Immunopathology and therapeutic immunointervention and Université Pierre et Marie Curie (UPMC-Paris-6), Centre de Recherche des Cordeliers, 15, rue de l’Ecole de Médecine, Paris 75006, France

Correspondence and offprint requests to: Dr Srini V. Kaveri, INSERM UMRS 872 Equipe 16, Centre de Recherche des Cordeliers, 15, rue de l’Ecole de Médecine, Paris 75006, France. Email: srini.kaveri@umrs681.jussieu.fr

Keywords: Fc gamma receptor; intravenous immunoglobulin; therapeutic IgG

The first 10% of the full text of this article appears below.



   Introduction
 
Immunoglobulin G (IgG) is the main serum glycoprotein responsible for detection and destruction of pathogens or their noxious products. IgG consists of Fab (‘fragment antigen binding’) regions, that recognize antigenic targets and provide diversity to antibodies, and Fc (‘fragment crystallizable’) regions, that allow antibodies to interact with Fc gamma receptors (Fc{gamma}R) on phagocytes (Fig. 1). Currently, four classes of Fc{gamma}R are identified: Fc{gamma}RI, Fc{gamma}RII, Fc{gamma}RIII and Fc{gamma}RIV [1]. For the initiation of a biological response against the bound antigen, IgGs rely on their constant Fc portion. CH2 domains of the Fc fragment contain complex oligosaccharide structures covalently attached to asparagine 297 of the heavy chain of the IgG [2,3]. The presence of a complex oligosaccharide structure modulates the functions of IgG, especially the . . . [Full Text of this Article]



   Overview of the study by Kaneko et al. [5]
 


   Discussion
 


   Perspective
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?